Patents Assigned to HEDGEPATH PHARMACEUTICALS, INC.
  • Treatment of prostate cancer using hedgehog pathway inhibitors
    Patent number: 10363252
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: July 30, 2019
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Treatment of lung cancer using hedgehog pathway inhibitors
    Patent number: 10328072
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: June 25, 2019
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Treatment and prognostic monitoring of non-cancerous proliferation disorders using hedgehog pathway inhibitors
    Patent number: 9968600
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 15, 2018
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Treatment and prognostic monitoring of cancerous proliferation disorders using Hedgehog pathway inhibitors
    Patent number: 9962381
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: May 8, 2018
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.
  • Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
    Patent number: 9192609
    Abstract: The present invention concerns methods for treating a proliferation disorder, such as prostate cancer, basal cell carcinoma, lung cancer, and other cancers, using an inhibitor of the Hedgehog pathway (HhP); and methods for monitoring subjects undergoing such treatments based on biomarkers and other criteria predictive of efficacy.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: November 24, 2015
    Assignee: HEDGEPATH PHARMACEUTICALS, INC.
    Inventors: Nicholas J. Virca, Francis E. O'Donnell, Jr.